Impact of Adjunctive Argatroban and Eptifibatide on Post-Stroke Outcomes
|
Reviewed & Translated by Dat Tien Nguyen, B.A, ScM.
|
Posted on October 21st, 2024
|
Treating ischemic stroke solely with intravenous thrombolytic agents results in approximately 30% recanalization of the occlusion. Argatroban, an arginine derivative, functions as an anticoagulant by binding to thrombin and inhibiting fibrin formation, while eptifibatide reduces platelet aggregation by blocking glycoprotein receptors. To evaluate the potential benefits of adding either argatroban or eptifibatide to standard thrombolytic therapy in reducing ischemic stroke complications, a study was sponsored by the National Institute of Neurological Disorders and Stroke.
The phase 3 clinical trial included 514 participants diagnosed with ischemic stroke who were scheduled to receive intravenous thrombolytic agents such as alteplase or tenecteplase. Patients were randomly assigned to receive either placebo, argatroban, or eptifibatide. Argatroban was administered with an initial bolus of 100 micrograms per kilogram of body weight, followed by a maintenance dose of 3 micrograms per kilogram for 12 hours. Eptifibatide was given at an initial dose of 135 micrograms per kilogram, with a maintenance dose of 0.75 micrograms per kilogram for 2 hours. Over the next 90 days, patients' health was monitored using the Rankin scale, where 0 represents no symptoms and 6 indicates death. Comparative analysis revealed that adding either argatroban or eptifibatide to standard intravenous thrombolytic therapy did not reduce post-stroke complications. In fact, argatroban significantly increased the mortality rate during the study period, with 24% of patients in the argatroban group dying, compared to 12% in the eptifibatide group and 8% in the control group. This unexpected rise in mortality associated with argatroban had not been observed in previous studies, and its cause remains unknown to the researchers.
The phase 3 clinical trial included 514 participants diagnosed with ischemic stroke who were scheduled to receive intravenous thrombolytic agents such as alteplase or tenecteplase. Patients were randomly assigned to receive either placebo, argatroban, or eptifibatide. Argatroban was administered with an initial bolus of 100 micrograms per kilogram of body weight, followed by a maintenance dose of 3 micrograms per kilogram for 12 hours. Eptifibatide was given at an initial dose of 135 micrograms per kilogram, with a maintenance dose of 0.75 micrograms per kilogram for 2 hours. Over the next 90 days, patients' health was monitored using the Rankin scale, where 0 represents no symptoms and 6 indicates death. Comparative analysis revealed that adding either argatroban or eptifibatide to standard intravenous thrombolytic therapy did not reduce post-stroke complications. In fact, argatroban significantly increased the mortality rate during the study period, with 24% of patients in the argatroban group dying, compared to 12% in the eptifibatide group and 8% in the control group. This unexpected rise in mortality associated with argatroban had not been observed in previous studies, and its cause remains unknown to the researchers.